Key Benefits of Cayuga Biotech's Technology

  • Improves safety
  • Streamlines treatment of injuries at hospitals
  • Saves the hospital and patient money

Key Publications

Kudela D. “Restoring Hemostasis Following Injury Using Polyphosphate-Coated Silica Nanoparticles.” The Federation of American Societies for Experimental Biology Journal. 2017, 31, 978.13.

Kudela D., Smith S.A., May-Masnou A., Braun, G.B., Pallaoro, A., Nguyen, C.K., Chuong, T.T., Nownes, S., Allen, R., Parker, N.R., Rashidi, H.H., Morrissey, J.H., Stucky, G.D. “Clotting Activity of Polyphosphate-Functionalized Silica Nanoparticles.” Angewandte Chemie International Edition. 2015, 54, 4018-4022.

Smith S.A., Choi S.H., Davis-Harrison R., Huyck J., Boettcher J., Rienstra C.M., Morrissey J.H. “Polyphosphate exerts differential effects on blood clotting, depending on polymer size.” Blood. 2010, 116, 4353-4359.

Smith S.A., Morrissey J.H. “Polyphosphate as a general procoagulant agent.” Journal of Thrombosis and Haemosasis. 2008, 6, 1750-1756.


Trauma-induced hemorrhage is the leading cause of death and reduced lifespan for people between the ages of 1 and 44. Often preventable, uncontrollable blood loss causes 40% of total trauma fatalities that occur within 24 hours after injury. There is a critical need for an intravenous hemostat that can function in prehospital conditions, whether on the battlefield or in the ambulance. A targeted, hemostatic agent that limits blood loss with a quick clearance time will greatly increase outcomes in trauma patients. Cayuga is working with the military to refine our technology for the battlefield.

Platelet storage pool deficiency is a group of bleeding disorders tied to problems with platelet granules. Granules secrete polyphosphate and other substances as part of coagulation. Such conditions lead to chronic, prolonged bleeding episodes and can complicate surgery treatment. Restoring polyphosphate levels in these bleeding disorders can help control bleeding episodes and improve patient quality of life.

In addition to platelet storage pool deficiency, polyphosphate has shown potential to help mitigate breakthrough bleeds in a variety of bleeding disorders - including hemophilia A, hemophilia B, emergency Coumadin reversal, and emergency reversal of novel oral anticoagulant medications – bypassing the blocked clotting mechanism to promote hemostasis.